

# Douglas J Veale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8522964/publications.pdf>

Version: 2024-02-01

233  
papers

21,208  
citations

15001

68  
h-index

12272

138  
g-index

245  
all docs

245  
docs citations

245  
times ranked

19367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 193-205.	0.5	16
2	Central Role of Semaphorin 3B in a Serum-Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 972-983.	2.9	9
3	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.5	12
4	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	0.9	20
5	Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications. <i>Nature Reviews Rheumatology</i> , 2022, 18, 398-414.	3.5	21
6	Pregnancy outcomes in women with psoriatic arthritis: comment on the article by Remaues et al. <i>Arthritis and Rheumatology</i> , 2022, 74, 1720-1720.	2.9	1
7	Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1224-1242.	0.5	15
8	COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. <i>Rheumatology</i> , 2021, 60, 902-906.	0.9	14
9	Long-term remission and biologic persistence rates: 12-year real-world data. <i>Arthritis Research and Therapy</i> , 2021, 23, 25.	1.6	30
10	The PD-1:PD-L1 axis in Inflammatory Arthritis. <i>BMC Rheumatology</i> , 2021, 5, 1.	0.6	29
11	First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. <i>BMJ Case Reports</i> , 2021, 14, e238851.	0.2	15
12	ACPA Status Correlates with Differential Immune Profile in Patients with Rheumatoid Arthritis. <i>Cells</i> , 2021, 10, 647.	1.8	20
13	Serum miRNA Signature in Rheumatoid Arthritis and "At-Risk Individuals". <i>Frontiers in Immunology</i> , 2021, 12, 633201.	2.2	36
14	The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis. <i>RMD Open</i> , 2021, 7, e001510.	1.8	2
15	Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. <i>Frontiers in Immunology</i> , 2021, 12, 672461.	2.2	9
16	Targeting GM-CSF in rheumatological conditions: risk of PAP. <i>Lancet Rheumatology</i> , The, 2021, 3, e473.	2.2	1
17	Rheumatoid arthritis CD14 <sup>+</sup> monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. <i>Clinical and Translational Immunology</i> , 2021, 10, e1237.	1.7	38
18	Functionally Mature CD1c <sup>+</sup> Dendritic Cells Preferentially Accumulate in the Inflammatory Arthritis Synovium. <i>Frontiers in Immunology</i> , 2021, 12, 745226.	2.2	8

#	ARTICLE	IF	CITATIONS
19	CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration, and Therapeutic Targeting. <i>Frontiers in Immunology</i> , 2021, 12, 722349.	2.2	19
20	A multidisciplinary approach to reproductive healthcare in women with rheumatic disease. <i>Irish Journal of Medical Science</i> , 2020, 189, 237-243.	0.8	8
21	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	1.0	3
22	Next-generation analysis of synovial tissue architecture. <i>Nature Reviews Rheumatology</i> , 2020, 16, 67-68.	3.5	4
23	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
24	Insulin-Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach. <i>Arthritis and Rheumatology</i> , 2020, 72, 896-902.	2.9	28
25	A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients. <i>Clinical Rheumatology</i> , 2020, 39, 747-754.	1.0	13
26	Enrichment of polyfunctional T cells in PsA synovial tissue. Response to: "Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells" by Raychaudhuri et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216814.	0.5	1
27	Monocyte-Derived Dendritic Cell Differentiation in Inflammatory Arthritis Is Regulated by the JAK/STAT Axis via NADPH Oxidase Regulation. <i>Frontiers in Immunology</i> , 2020, 11, 1406.	2.2	22
28	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
29	Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1760-1767.	1.0	29
30	Targeting bioenergetics prevents CD4 T cell-mediated activation of synovial fibroblasts in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2816-2828.	0.9	41
31	Arthroscopic Guided Synovial Biopsies. <i>Frontiers in Medicine</i> , 2020, 7, 604582.	1.2	1
32	Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint. <i>JCI Insight</i> , 2020, 5, .	2.3	44
33	Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. <i>Irish Journal of Medical Science</i> , 2019, 188, 169-172.	0.8	11
34	Association of the Rheumatoid Arthritis Severity Variant rs26232 with the Invasive Activity of Synovial Fibroblasts. <i>Cells</i> , 2019, 8, 1300.	1.8	3
35	Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 350-354.	0.5	51
36	Dysregulated miR-125a promotes angiogenesis through enhanced glycolysis. <i>EBioMedicine</i> , 2019, 47, 402-413.	2.7	36

#	ARTICLE	IF	CITATIONS
37	STAT3 Mediates the Differential Effects of Oncostatin M and TNF $\alpha$ on RA Synovial Fibroblast and Endothelial Cell Function. <i>Frontiers in Immunology</i> , 2019, 10, 2056.	2.2	58
38	Interleukin-6 does not upregulate pro-inflammatory cytokine expression in an ex vivo model of giant cell arteritis. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz011.	0.3	7
39	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. <i>Arthritis Care and Research</i> , 2019, 71, 1387-1395.	1.5	38
40	Synovial Tissue Biopsy Research. <i>Frontiers in Medicine</i> , 2019, 6, 72.	1.2	12
41	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1616-1625.	2.9	14
42	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
43	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
44	Reproductive health outcomes in women with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 850-852.	0.5	7
45	Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. <i>Journal of Autoimmunity</i> , 2019, 96, 86-93.	3.0	28
46	Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. <i>Clinical Immunology</i> , 2019, 199, 47-51.	1.4	7
47	The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis. <i>Journal of Rheumatology</i> , 2019, 46, 1365-1368.	1.0	7
48	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , 2019, 58, 197-205.	0.9	68
49	Readability and Quality of Online Information on Osteoarthritis: An Objective Analysis With Historic Comparison. <i>Interactive Journal of Medical Research</i> , 2019, 8, e12855.	0.6	33
50	Performance characteristics and predictors of temporal artery ultrasound for the diagnosis of giant cell arteritis in routine clinical practice in a prospective cohort. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 72-78.	0.4	5
51	Angiogenesis in Inflammatory Arthritis. <i>Israel Medical Association Journal</i> , 2019, 21, 345-352.	0.1	8
52	Knee joint synovitis: study of correlations and diagnostic performances of ultrasonography compared with histopathology. <i>RMD Open</i> , 2018, 4, e000616.	1.8	17
53	Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 523-528.	1.6	69
54	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50

#	ARTICLE	IF	CITATIONS
55	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
56	Hypoxia, oxidative stress and inflammation. <i>Free Radical Biology and Medicine</i> , 2018, 125, 15-24.	1.3	343
57	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
58	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
59	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	1.6	29
60	Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 95.	1.6	70
61	JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1959-1970.	2.9	97
62	The pathogenesis of psoriatic arthritis. <i>Lancet</i> , 2018, 391, 2273-2284.	6.3	347
63	Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 85.	1.6	83
64	The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 185.	1.2	64
65	Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1815-1824.	0.5	38
66	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. <i>PLoS ONE</i> , 2018, 13, e0192704.	1.1	82
67	Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis. <i>JCI Insight</i> , 2018, 3, .	2.3	30
68	Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosis Factor Inhibition Therapy. <i>Musculoskeletal Care</i> , 2017, 15, 23-35.	0.6	19
69	Resolution of TLR2-induced inflammation through manipulation of metabolic pathways in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2017, 7, 43165.	1.6	66
70	Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells. <i>Journal of Immunology</i> , 2017, 198, 2249-2259.	0.4	113
71	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
72	Brief Report: Genetic Variation of the $\alpha 1$ -Antitrypsin Gene Is Associated With Increased Autoantibody Production in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1576-1579.	2.9	11

#	ARTICLE	IF	CITATIONS
73	CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression. <i>Journal of Immunology</i> , 2017, 198, 4490-4501.	0.4	73
74	Cellular and molecular perspectives in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2017, 39, 343-354.	2.8	93
75	Response to: "Regulatory role of the JAK/STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis" by Raychaudhuri et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e37-e37.	0.5	3
76	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
77	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	1.5	58
78	Dr. Wiland, et al, reply. <i>Journal of Rheumatology</i> , 2017, 44, 259.2-259.	1.0	0
79	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 2404-2406.	2.9	0
80	Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2114-2123.	2.9	54
81	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. <i>Nature Medicine</i> , 2017, 23, 938-944.	15.2	223
82	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
83	05.02...Differentiating patient responses in rheumatoid arthritis " systems analysis of key molecular networks. , 2017, , .		0
84	02.33...Altered bioenergetics, mitochondrial function and pro-inflammatory pathways in ra synovium in response to tofacitinib. , 2017, , .		0
85	01.04...Enrichment of activated cd141+ dendritic cells in inflammatory arthritis. , 2017, , .		0
86	Synovium. , 2017, , 20-33.		6
87	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82
88	A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF $\alpha$ treatment of psoriatic arthritis. <i>Proteomics - Clinical Applications</i> , 2016, 10, 645-662.	0.8	26
89	Ustekinumab for the treatment of refractory giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1578-1579.	0.5	87
90	Dysregulated bioenergetics: a key regulator of joint inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2192-2200.	0.5	172

#	ARTICLE	IF	CITATIONS
91	Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 385-397.	3.5	267
92	The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1268-1277.	1.0	15
93	Success Rate and Utility of Ultrasound-guided Synovial Biopsies in Clinical Practice. <i>Journal of Rheumatology</i> , 2016, 43, 2113-2119.	1.0	32
94	Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	0.8	47
95	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter “Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	1.0	30
96	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.5	743
97	Patient global assessment in psoriatic arthritis “what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	0.8	35
98	Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 311-315.	0.5	117
99	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.5	56
100	Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1392-1398.	0.5	57
101	Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A. <i>Arthritis and Rheumatology</i> , 2015, 67, 2447-2456.	2.9	57
102	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.5	7
103	Migrating Polyarthritis as a Feature of Occult Malignancy: 2 Case Reports and a Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-7.	0.2	6
104	Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1275-1283.	0.5	125
105	Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 153.	1.6	51
106	Therapeutic targets in psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 489-499.	0.3	1
107	Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity. <i>Journal of Immunology</i> , 2015, 195, 528-540.	0.4	76
108	What makes psoriatic and rheumatoid arthritis so different?. <i>RMD Open</i> , 2015, 1, e000025-e000025.	1.8	75

#	ARTICLE	IF	CITATIONS
109	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , 2015, 161, 2-10.	1.4	45
110	Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis. <i>Clinical Rheumatology</i> , 2015, 34, 1857-1865.	1.0	20
111	C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11618-11623.	3.3	26
112	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. <i>Arthritis Care and Research</i> , 2014, 66, 1597-1603.	1.5	11
113	Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research. <i>EBioMedicine</i> , 2014, 1, 95-96.	2.7	1
114	Notch-1 mediates endothelial cell activation and invasion in psoriasis. <i>Experimental Dermatology</i> , 2014, 23, 113-118.	1.4	23
115	Redox-Mediated Angiogenesis in the Hypoxic Joint of Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3300-3310.	2.9	41
116	Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 951-953.	0.5	6
117	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.5	314
118	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
119	Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). <i>European Journal of Internal Medicine</i> , 2013, 24, 597-603.	1.0	93
120	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. <i>American Journal of Pathology</i> , 2013, 183, 1243-1257.	1.9	29
121	Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. <i>Rheumatology</i> , 2013, 52, 1572-1582.	0.9	47
122	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
123	Psoriatic arthritis: recent progress in pathophysiology and drug development. <i>Arthritis Research and Therapy</i> , 2013, 15, 224.	1.6	22
124	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 284-285.	6.7	0
125	Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1080-1088.	0.5	87
126	Periarticular Bone Gain at Proximal Interphalangeal Joints and Changes in Bone Turnover Markers in Response to Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 653-662.	1.0	25



#	ARTICLE	IF	CITATIONS
127	Necrotizing Fasciitis in Patients on Methotrexate Therapy. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 289-291.	0.5	3
128	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. <i>Arthritis Research and Therapy</i> , 2013, 15, R221.	1.6	28
129	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. <i>PLoS ONE</i> , 2013, 8, e66456.	1.1	27
130	Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?. <i>Journal of Leukocyte Biology</i> , 2013, 95, 233-241.	1.5	55
131	Pulmonary Fibrosis in Systemic Sclerosis. <i>Journal of Thoracic Imaging</i> , 2012, 27, 44-50.	0.8	4
132	Miliary Nodularity in a Patient Receiving TNF Inhibitors Is Not Always Miliary Tuberculosis: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 651-652.	1.0	1
133	Enthesitis in Psoriatic Disease. <i>Dermatology</i> , 2012, 225, 100-109.	0.9	39
134	Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 582-588.	0.5	70
135	Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. <i>Arthritis and Rheumatism</i> , 2012, 64, 3290-3301.	6.7	17
136	Acute-phase serum amyloid A regulates tumor necrosis factor $\alpha$ and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. <i>Arthritis and Rheumatism</i> , 2012, 64, 1035-1045.	6.7	86
137	Notch $\beta$ mediates hypoxia-induced angiogenesis in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2104-2113.	6.7	69
138	Orphan nuclear receptor NR4A2 induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription. <i>Arthritis and Rheumatism</i> , 2012, 64, 2126-2136.	6.7	37
139	MRI-Based Visualisation and Quantification of Rheumatoid and Psoriatic Arthritis of the Knee. <i>Mathematics and Visualization</i> , 2012, , 45-59.	0.4	1
140	Introduction to "Synovitis - an inflammation of joints destroying the bone". <i>Swiss Medical Weekly</i> , 2012, 142, w13712.	0.8	0
141	Synovial Tissue Analysis for the Discovery of Diagnostic and Prognostic Biomarkers in Patients with Early Arthritis: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 2068-2072.	1.0	33
142	The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort. <i>Value in Health</i> , 2011, 14, 921-927.	0.1	6
143	Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R121.	1.6	55
144	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. <i>Arthritis Research and Therapy</i> , 2011, 13, R7.	1.6	41

#	ARTICLE	IF	CITATIONS
145	Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. <i>Arthritis Research and Therapy</i> , 2011, 13, R33.	1.6	70
146	Macrophages in Synovial Inflammation. <i>Frontiers in Immunology</i> , 2011, 2, 52.	2.2	137
147	IL-17A Expression Is Localised to Both Mononuclear and Polymorphonuclear Synovial Cell Infiltrates. <i>PLoS ONE</i> , 2011, 6, e24048.	1.1	61
148	Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease. <i>PLoS ONE</i> , 2011, 6, e27182.	1.1	12
149	Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNF $\pm$ therapy medication. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 11.	0.8	8
150	New therapies and new goals for psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 874-876.	6.7	10
151	Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. <i>Arthritis and Rheumatism</i> , 2011, 63, 923-932.	6.7	52
152	Clinical images: Infliximab therapy of polyarticular small joint sarcoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2030-2030.	6.7	5
153	Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2172-2182.	6.7	89
154	Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. <i>Arthritis and Rheumatism</i> , 2011, 63, 3263-3273.	6.7	44
155	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 423-427.	0.5	101
156	Is Remission a More Realistic Goal in Psoriatic Arthritis?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 3-7.	1.2	2
157	Toll-Like Receptor 2 Induced Angiogenesis and Invasion Is Mediated through the Tie2 Signalling Pathway in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2011, 6, e23540.	1.1	62
158	How early should psoriatic arthritis be treated with a TNF-blocker?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 393-396.	2.0	6
159	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. <i>Rheumatology International</i> , 2010, 30, 1571-1580.	1.5	8
160	Angiogenesis and blood vessel stability in inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 711-721.	6.7	132
161	A qualitative study of work participation in early rheumatoid arthritis. <i>International Journal of Therapy and Rehabilitation</i> , 2010, 17, 24-33.	0.1	17
162	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 706-714.	0.5	39

#	ARTICLE	IF	CITATIONS
163	Synovial tissue hypoxia and inflammation in vivo. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1389-1395.	0.5	198
164	Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1386-1394.	1.0	114
165	Comparison of interferon $\gamma$ release assays and conventional screening tests before tumour necrosis factor $\alpha$ blockade in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 181-185.	0.5	72
166	Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1172-1178.	0.5	87
167	Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model. <i>Journal of Immunology</i> , 2010, 184, 6427-6437.	0.4	92
168	Irish Smokers with Rheumatoid Arthritis Suffer More Than Their Nonsmoking Counterparts: Table 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1062-1062.	1.0	4
169	A Role for the High-Density Lipoprotein Receptor SR-B1 in Synovial Inflammation via Serum Amyloid-A. <i>American Journal of Pathology</i> , 2010, 176, 1999-2008.	1.9	49
170	Remission in psoriatic arthritis: is it possible and how can it be predicted?. <i>Arthritis Research and Therapy</i> , 2010, 12, R94.	1.6	77
171	Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. <i>Pharmacoeconomics</i> , 2010, 28, 477-487.	1.7	51
172	Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 401-4.	0.4	18
173	Psoriatic Arthritis Management Update - Biotherapeutic Options. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 65-68.	2.2	13
174	Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers. <i>Journal of Rheumatology</i> , 2009, 36, 1800-1802.	1.0	107
175	An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions. <i>Irish Journal of Medical Science</i> , 2009, 178, 497-501.	0.8	2
176	Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor- $\alpha$ , Oncostatin M and response to biologic therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, R113.	1.6	150
177	Hypoxia Activates NF- $\kappa$ B-Dependent Gene Expression Through the Canonical Signaling Pathway. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 2057-2064.	2.5	103
178	The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 196-200.	0.5	134
179	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
180	A Topological Approach to Quantitation of Rheumatoid Arthritis. <i>Mathematics and Visualization</i> , 2008, , 27-37.	0.4	1

#	ARTICLE	IF	CITATIONS
181	Functional characterization of NF- $\kappa$ B inhibitor-like protein 1 (NF $\kappa$ BIL1), a candidate susceptibility gene for rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2007, 16, 3027-3036.	1.4	28
182	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 778-781.	0.5	53
183	Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1656-1660.	0.5	20
184	Recombinant human anti- $\alpha$ transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
185	Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. <i>Arthritis and Rheumatism</i> , 2007, 56, 2919-2928.	6.7	45
186	Angiogenesis in Arthritis. <i>Methods in Molecular Medicine</i> , 2007, , 343-357.	0.8	18
187	Angiogenesis in Psoriasis and Psoriatic Arthritis. , 2007, , 61-64.		0
188	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. <i>Journal of Rheumatology</i> , 2007, 34, 620-2.	1.0	50
189	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	1.0	57
190	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74
191	Angiogenesis in Arthritis: Methodological and Analytical Details. , 2007, 135, 343-358.		9
192	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1003-1012.	0.6	105
193	Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 941-947.	1.4	63
194	Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF- $\kappa$ B-dependent signal transduction pathway. <i>Arthritis and Rheumatism</i> , 2006, 54, 105-114.	6.7	134
195	Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. <i>Arthritis and Rheumatism</i> , 2006, 54, 3152-3162.	6.7	80
196	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3962-3970.	6.7	632
197	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". <i>Journal of Rheumatology</i> , 2006, 33, 552-7.	1.0	13
198	Angiogenesis in psoriasis and psoriatic arthritis: Clues to disease pathogenesis. <i>Current Rheumatology Reports</i> , 2005, 7, 325-329.	2.1	52

#	ARTICLE	IF	CITATIONS
199	A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 859-864.	0.5	158
200	Synovial tissue inflammation in early and late osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1263-1267.	0.5	779
201	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005, 7, R80.	2.0	75
202	Synovial tissue analysis in clinical trials. <i>Journal of Rheumatology</i> , 2005, 32, 2481-4.	1.0	21
203	True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin A? <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1344-1346.	0.5	74
204	Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 162-169.	0.5	218
205	Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 342-347.	0.5	147
206	Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. <i>Arthritis and Rheumatism</i> , 2003, 48, 3085-3095.	6.7	110
207	Angiopoietins, growth factors, and vascular morphology in early arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 260-8.	1.0	157
208	Management of Spondyloarthropathy. <i>Drugs</i> , 2002, 62, 2349-2359.	4.9	8
209	Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2002, 46, 366-372.	6.7	214
210	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 837-839.	6.7	44
211	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. <i>Arthritis and Rheumatism</i> , 2002, 46, 2034-2038.	6.7	262
212	Psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 523-35.	1.4	4
213	Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. <i>Journal of Rheumatology</i> , 2002, 29, 2371-8.	1.0	79
214	(i) Medical management of the rheumatoid hand. <i>Orthopaedics and Trauma</i> , 2001, 15, 323-328.	0.3	0
215	Pathways of cell activation in spondyloarthropathies. <i>Current Rheumatology Reports</i> , 2001, 3, 435-442.	2.1	5
216	Pathogenesis of psoriatic arthritis. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 333-337.	0.6	31

#	ARTICLE	IF	CITATIONS
217	Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2024-2028.	6.7	109
218	Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific Association with Rheumatoid Arthritis. <i>Infection and Immunity</i> , 2001, 69, 1821-1831.	1.0	20
219	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. <i>Journal of Clinical Investigation</i> , 2001, 107, 519-528.	3.9	36
220	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. <i>Arthritis and Rheumatism</i> , 2000, 43, 2762-2770.	6.7	611
221	What practical skills do rheumatologists of the future need?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000, 14, 635-648.	1.4	5
222	Macrovascular disease and systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 39-43.	0.5	150
223	Case definition of psoriatic arthritis. <i>Lancet, The</i> , 2000, 356, 2095.	6.3	2
224	Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 342-349.	0.5	60
225	Synovial Cytokine and Growth Factor Regulation of MMPs/TIMPs: Implications for Erosions and Angiogenesis in Early Rheumatoid and Psoriatic Arthritis Patients. <i>Annals of the New York Academy of Sciences</i> , 1999, 878, 619-621.	1.8	64
226	The relationship between pityriasis rubra pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. <i>Arthritis and Rheumatism</i> , 1999, 42, 1998-2001.	6.7	33
227	Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. <i>Arthritis and Rheumatism</i> , 1998, 41, 663-669.	6.7	110
228	Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 1997, 40, 352-357.	6.7	60
229	Cell Adhesion Molecules in Rheumatoid Arthritis. <i>Drugs and Aging</i> , 1996, 9, 87-92.	1.3	32
230	Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. <i>British Journal of Dermatology</i> , 1995, 132, 32-38.	1.4	50
231	Increased prevalence of symptomatic macrovascular disease in systemic sclerosis.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 853-855.	0.5	109
232	Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 893-900.	6.7	230
233	Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis. <i>HRB Open Research</i> , 0, 4, 60.	0.3	0